Layla

Layla is a biotechnology company focused on the discovery and development of RNA-based medicines to treat aging-related diseases and promote tissue regeneration. The company utilizes a proprietary platform that integrates computational biology with high-throughput screening to identify novel RNA targets involved in cellular senescence and metabolic decline. Layla's initial research programs are centered on liver regeneration and the treatment of chronic liver diseases through the modulation of age-associated pathways. By targeting the fundamental biological drivers of aging, the company aims to extend human healthspan and develop transformative therapies for conditions with high unmet medical needs. Layla is part of the Apeiron Investment Group ecosystem and operates at the intersection of longevity science and RNA technology.